Editas Medicine Inc EDIT has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.
- The biotech was mum on the reasoning for the termination, disclosed in a Securities and Exchange Commission filing.
- The termination that occurred today is effective immediately.
- According to the SEC filing, Michaels will receive her base salary for another 12 months.
- Related: Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate.
- RBC Capital Markets analyst called the news "incrementally negative" and wrote in a note that the firing "does not boost confidence" in a company with mixed clinical signals for LCA10 and high management turnover.
- Analyst Luca Issi remains on the sidelines with a Sector Perform rating and $40 price target on Editas shares given what he views as mixed data for its lead asset, a "crowded" SCD space, and an oncology pipeline that remains early.
- Price Action: EDIT shares are down 7.40% at $17.89 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in